I think the market has missed this one. What a huge opportunity for both ALS sufferers and investors. The early data is compelling. FDA approved Relyvrio based on a survival rate of 75% over a year. PAA has had ZERO deaths over an even longer period. If the upcoming data replicates this then FDA approval seems certain. Investors you've got three weeks maximum to grab this opportunity. DYOR
Ann: Extension Study Begins, Analysis Suggests Survival Benefit, page-33
-
- There are more pages in this discussion • 165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $91.22M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 21.5¢ | 20.5¢ | $174.5K | 841.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 458470 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 144453 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |